Evofem Biosciences Inc
Change company Symbol lookup
Select an option...
EVFM Evofem Biosciences Inc
CCL Carnival Corp
CLPR Clipper Realty Inc
VGI Virtus Global Multi-Sector Income Fund
VDE Vanguard Energy Index Fund ETF Shares
VCV Invesco California Value Municipal Income Trust
VCSH Vanguard Short-Term Corporate Bond Index Fund ETF Shares
VBR Vanguard Small-Cap Value Index Fund ETF Shares
V Visa Inc
UPS United Parcel Service Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company’s product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.

Premarket

Last Trade
Delayed
$3.06
-0.01 (-0.33%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$3.07
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
973

10-day average volume:
4,085,963
973

Company Profile

Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company’s product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
149.27x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

June 2020
Current Month
1.9M
Previous Month
3.8M
Percent of Float
2.44%
Days to Cover
0.2544 Days

Share Information

EVFM is in a share class of common stock
Float
76.7M
Shares Outstanding
78.1M
Institutions Holding Shares
74
49.64%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Thomas LynchChmn.
  • Saundra PelletierPres.
  • Justin J. FileCFO
  • Alexander A. FitzpatrickExec.VP
  • Russell BarransOther

Address

Insider Trading

During the most recent quarter, 886K shares were bought, and 9M shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.